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The role of the percutaneous coronary intervention 
in acute coronary syndrome
Freek W.A. Verheugt
A b s t r a c t  
Most cases of acute coronary syndromes are caused by coronary thrombosis on
top of an atherosclerotic plaque. Besides intensive antithrombotic therapy,
dilatation of the culprit lesion has now been standard of care. Sealing and stenting
of the culprit lesion may prevent recurrent coronary thromboses, but also carries
a risk of thromboembolic and atheroembolic complications. Furthermore,
percutaneous coronary intervention after acute coronary syndrome needs even
more intense antithrombotic therapy, which may further increase the risk of
bleeding in general and the need for transfusion in particular, which is associated
with increased risk of early and late mortality. Yet, percutaneous coronary
intervention is necessary in many patients and in most of them it leads to a
definitive solution of a coronary plaque rupture that lead to the acute coronary
syndrome. 
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intervention.
The history of percutaneous coronary intervention
Ischemic heart disease is the major cause of mortality and one of the
major causes of morbidity in the Western world. Current treatment consists
of medical therapy and, in selected cases, of revascularisation of occluded
or narrowed coronary arteries. Coronary bypass surgery was first applied
in the early sixties by René Favoloro in Cleveland and significantly
contributed to quality and quantity of life in patients with symptomatic
ischemic heart disease. In 1977 Andreas Grüntzig introduced percutaneous
transluminal coronary angioplasty, which technique postponed or even
avoided coronary surgery in many symptomatic patients. Nowadays,
percutaneous coronary intervention (PCI) largely outnumbers coronary
artery bypass surgery in the Western world. 
Possible benefit of revascularisation in acute myocardial ischemia
Early angiographic observations in the seventies have shown that most
cases of acute myocardial ischemia are caused by coronary atherosclerosis.
In transmural myocardial infarction (ST segment elevation on the presenting
ECG) an occlusion of a major epicardial coronary artery was observed in
most cases [1]. Since the introduction of intracoronary thrombolytic therapy
for acute myocardial infarction it became clear that the nature of this
occlusion is thrombotic [2]. It became also apparent that after lytic therapy
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many coronary stenoses that had produced acute
occlusion probably not have been very severe to
start with [3]. From these observations the
hypothesis emanated, that coronary thrombosis is
an acute phenomenon and may occur on not very
tight coronary stenoses. From histopathology it
became clear that rupture of a lipid laden coronary
plaque may initiate acute coronary thrombosis [4].
Three types of coronary thrombosis in acute
coronary syndromes have been distinguished:
occlusive, non-occlusive and dispersive coronary
thrombosis. Occlusive coronary thrombosis usually
causes ST-segment elevation myocardial infarction
with Q-wave formation. Non-occlusive thrombosis
is most seen in non-ST-segment elevation acute
coronary syndromes, and may (non-ST elevation
myocardial infartcion or NSTEMI) or may not lead
to myocardial necrosis (unstable angina). Dispersive
thrombosis has been observed downstream of a
ruptured atherosclerotic plaque in patients with
sudden cardiac death, apparently resulting in
malignant electric instability.
The current nomenclature of the syndrome of
acute myocardial ischemia (acute coronary
syndrome) is based on the presenting ECG (Figure 1)
and the occurrence of subsequent myocardial
necrosis. If myocardial markers are found in the
plasma, myocardial infarction is diagnosed. If not,
unstable angina is the final diagnosis. Intervening
with revascularisation may influence he course of
the acute coronary syndrome by mitigating or even
aborting myocardial necrosis [5].
Percutaneous coronary intervention in 
ST-elevation myocardial infarction
Reperfusion therapy for ST-elevation acute
coronary syndromes aims at early and complete
recanalization of the infarct-related artery in order
to salvage myocardium and improve both early and
late clinical outcomes. The benefit rises expo-
nentially the earlier therapy is initiated. The highest
number of lives saved is within the first hour after
symptom onset: the golden hour. The exponential
form of the curve relating mortality to time-to-
reperfusion has major implications for the timing
of treatment. The impact of delay in time-to-
treatment lessens as the duration of ischemia
lengthens. Consequently, reducing delays will have
a much more positive return in patients presenting
early for those presenting late. These considerations
have provided a strong incentive for the initiation
of very early reperfusion therapy.
Thrombolytic therapy has become the gold
standard of reperfusion therapy since the 80s.
Although thrombolytic therapy for acute myocardial
infarction is very widely applicable, it is only
successful in restoring full early patency in about
50% of patients and has a low, but significant risk
of severe side effects. Primary angioplasty carried
out as an alternative to thrombolysis circumvents
the cost and risk of thrombolytic therapy and might
restore patency in nearly 90% of cases. Outcome
of randomised trials of primary angioplasty vs.
thrombolytic therapy in acute myocardial infarction
are convincingly in favour of angioplasty [6]. As
primary thrombolysis has improved (bolus lytic
therapy with bolus and subcutaneous low-mole-
cular weight heparin), also primary angioplasty has
become even more effective using routine coronary
stenting [7]. However, pre-angioplasty admini-
stration of drugs (thrombolytics, glycoprotein
receptor IIb/IIIa antagonists or both) has not been
successful in improving the results of primary
angioplasty [8, 9]. This approach is currently called
“facilitated angioplasty” is meant to speed up
reperfusion and indeed is associated with better
pre-angioplasty coronary patency, but it increases
bleeding. An interesting new development in
improving the results of primary angioplasty is
thrombosuction prior to balloon inflation. This may
result in better reperfusion [10] and improved
survival [11], but this venue has to be established
in more trials.
As primary angioplasty proves to be a valuable
and more effective alternative to thrombolysis,
acute angioplasty is expensive, needs a costly
infrastructure and, therefore, is not widely appli-
cable. Transport to a tertiary center for primary
angioplasty, however, seems feasible and safe.
Although it delays time to treatment with a further
60 min, it tends to save lives and strokes and
significantly reduces reinfarction [12]. Yet, the
mechanism of improved outcome with primary
angioplasty is not fully clear. Post-angioplasty
patency figures are usually given in the 90 to 95%
range. However, in GUSTO IIb, the largest study of
primary angioplasty vs. lytic therapy, core lab read
TIMI-3 flow in the angioplasty patients did not
exceed 75%. This comes close to the figures in the
studies combing half-dose lytic with abciximab,
which in 2 megatrials did not result in better
survival [13]. Therefore, there may be other
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Figure 1. Current nomenclature of acute coronary
syndromes depending on the presenting ECG and
occurrence of subsequent myocardial necrosis
STEMI – ST-elevation myocardial infarction, 
NSTEMI – non-ST-elevation myocardial infarction
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mechanisms operative in the benefit of primary
angioplasty. These may include less reocclusion [14],
or the knowledge of the coronary anatomy, by
which high-risk patients in the need for urgent
coronary surgery, can be identified early.
As pointed out earlier, timing of reperfusion
therapy is important. Also with percutaneous
intervention mortality deteriorates as symptom-to-
balloon time increases [15]. Intervention later than
12 h is not thought to be useful, although myocardial
salvage beyond 12 h has been proven by scintigraphy
[16]. But opening occluded infarct arteries beyond 
72 h has not shown clinically beneficial in the large
OAT (Open Artery Trial) study [17].
Percutaneous coronary intervention 
in non-ST-elevation myocardial infarction
Unlike in STEMI acute total coronary occlusion is
not common in non-STEMI. Therefore, reperfusion
therapy with thrombolysis is not appropriate and
may even be harmful [18]. Yet, myocardial ischemia
is the key element in non-ST-elevation myocardial
infarction and should be treated with anti-ischemic
therapy consisting of nitroglycerin and β-blockade.
Early coronary intervention in this syndrome is
feasible as found out already in the mid 80s [19]. It
usually relieves myocardial ischemia and is a good
prognosticator. However, randomized trials com-
paring an early invasive strategy to a conservative
or a more selective approach did not show 
a mortality benefit on the short [20] and long term
[21]. The reason for this may be that the benefit of
early intervention may be balanced by possible harm
(see below). Current medical therapy of non-STEMI
besides anti-ischemic drugs includes aspirin,
clopidogrel, (low molecular) heparin, statins and ACE-
inhibitors. Each of these medical interventions on
its own has shown efficacy in acute myocardial
ischemia. Therefore, it is difficult to show a mortality
benefit over this broad-based medical background.
Finally, myocardial infarction may be less with an
early intervention, but myocardial infarction is 
a cumbersome endpoint in the randomized clinical
trials in this syndrome. It is both an entry criterion
and an endpoint at the same time, and it can be
considered as a complication of the treatment
(periprocedural during and after an intervention, or
spontaneous by not performing an intervention).
Such an endpoint is difficult to adjudicate, since the
above trials are open by design.
Timing of percutaneous intervention in non-ST-
elevation myocardial infarction is also a matter of
debate. Early intervention may prevent further
infarction, but also may be harmful given the
thrombotic milieu of the culprit lesion. Medical
passivation of coronary plaques may be beneficial,
but will take time during which recurrent infarction
may occur. So far there is only one relatively small
randomized trial comparing very early (< 6 h after
admission) vs. late (> 3 days) intervention, which
showed a significant benefit of early treatment in
the prevention of recurrent infarction [22].
Complications of percutaneous coronary
intervention
Complications of percutaneous coronary inter-
vention can be either cardiac or vascular. Cardiac
consequences are cardiac death and myocardial
infarction, whereas vascular complications mainly
consist of spontaneous bleeding and of bleeding at
the vascular access site.
Myocardial infarction and death
Both in STEMI and non-STEMI coronary plaque
rupture is a pivotal process. Intervention in 
a recently ruptured plaque may be harmful by
causing athero-embolic and thromboembolic
phenomena resulting in extending or recurrent
myocardial infarction. Although meant to improve
myocardial perfusion and stabilizing the ruptured
plaque percutaneous intervention may lead to
(re)infarction, which can amount to 1-2% in STEMI
[6] and up to 5% in non-STE acute coronary
syndrome [23].
Bleeding
In general the hemostatic system seems to play
an important role in bleeding complications. In
elective PCI severe bleeding may be seen in up to
5% of cases depending on definition. Intervention
in unstable coronary disease may have more
vascular complications. Since non-STEMI should be
treated with at least 3 antithrombotic agents
(aspirin, clopidogrel and heparin), bleeding is more
common than in elective intervention. 
Age is strong risk factor for bleeding as well as
renal dysfunction [24]. Blood transfusions in this
syndrome do not seem to improve outcome. On the
contrary, death and myocardial infarction triple after
transfusion [24].
Conclusions
Although not everywhere available, early
percutaneous coronary intervention has gained an
important place in the early management of acute
coronary syndromes. Usually it offers prompt relief
of myocardial ischemia and probably inhibits
propagation of ongoing myocardial infarction. In 
ST-elevation myocardial infarction emergent
intervention reduces early and late mortality,
whereas in non-ST elevation acute coronary
syndrome myocardial (re)infarction but not long-
term mortality is effectively diminished with early
coronary intervention. Percutaneous intervention is
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associated with an inherent bleeding risk, which
may result in increased mortality. Excess bleeding
complications are probably due to the widespread
use of strong antiplatelet and anticoagulant
medication used in the syndrome.
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